18 results for «113»
18 results
Transcatheter tricuspid valve replacement - LIVE case
Recommended by PCR
15 May 2024 – From EuroPCR 2024
An 82-year-old male with a history of STEMI in 2013, stroke in 2018, cancer, and permanent AF, presented with acute heart failure with predominant right-side failure. Severe tricuspid regurgitation was identified.
The operators implanted an Evoque valve percutaneously under TEE guidance and general anaesthesia via the venous...

Advanced mitral TEER - LIVE case
Recommended by PCR
24 Nov 2024 – From PCR London Valves 2024
Join us for a LIVE case followed by a recorded case highlighting advanced treatments for severe secondary mitral regurgitation:
- A 75-year-old man with permanent AF, a history of CABG, and symptomatic severe secondary MR (atrial and ischemic causes) with low LV function (45%) underwent mitral repair with...

Imaging-guided left main PCI - LIVE case
Recommended by PCR
17 May 2024 – From EuroPCR 2024
A 53-year-old male with a history of advanced malignancy (lung adenoma) and mid LAD PCI last year, along with multiple risk factors (hypertension, dyslipidemia, diabetes, and smoking), presented with angina and a positive stress test and CT. The angiography and CT showed significant left main stenosis...

Transcatheter options for degenerated surgical aortic valves - LIVE case
Recommended by PCR
08 Feb 2025 – From PCR Tokyo Valves 2025
A 77-year-old male with a history of SAVR in 2011 (Magna Ease 23) and moderate chronic kidney disease, with preservedLV function, presented with symptomatic severe aortic regurgitation and stenosis, associated with severe MR.
A Sapien 3 Ultra Resilia 23 valve was implanted under local anesthesia, with hemodynamic...

Transcatheter management of failed THV - LIVE case
Recommended by PCR
09 Feb 2025 – From PCR Tokyo Valves 2025
An 84-year-old woman with diabetes mellitus, frailty (5/6), preserved LV function, and aortic stenosis previously treated with CoreValve 26 mm in 2016, presented with symptomatic degenerative stenosis of the valve.
A Sapien 3 (23 mm) was implanted without predilatation but with post-dilatation under general anaesthesia, using cerebral...

iFR-SWEDEHEART: iFR vs FFR-Guided Coronary Revascularisation
04 Nov 2021
Nicola Ryan reviews the iFR Swedeheart multicenter, randomized, controlled, open-label clinical trial using the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) for enrolment randomisation and follow up. At one year follow up iFR guided revascularisation was shown to be non-inferior to FFR guided revascularisation, these results...

Author

Catalysing a more equitable workforce in medicine – Women as One - EuroPCR 2022
19 May 2022
Founded in 2019 by Marie-Claude Morice and Roxana Mehran, the mission of Women as One is to promote talent in medicine by providing unique professional opportunities to women physicians.

Author

Author

Frequency and safety of bioprosthetic valve fracture in patients undergoing valve in valve TAVR for failed surgical valves using the SAPIEN 3/Ultra Valves: Insights from real-world data
19 Sep 2022
Michele Pighi provides his take on this trial which aimed to compare the safety and efficacy of VIV-TAVI with or without bioprosthetic valve fracture. It was presented by Santiago Garcia during the TCT Congress 2022.

Author

Complicated subendothelial dissection during left anterior descending coronary artery – first diagonal branch bifurcation treatment with Culotte technique
06 Jan 2025
Learn more about troubleshooting and tailor-made treatment combining 2D and 3D OCT thanks to this image in cardiology!

Cardiawave announces positive six-month data from valvosoft pivotal study at transcatheter cardiovascular therapeutics (TCT) conference
28 Oct 2024

Primary and secondary outcomes of the Women's Ischemia Trial to reduce events in non-obstructive coronary artery disease (WARRIOR)
31 Mar 2025
Nicola Ryan provides her take on the WARRIOR trial which was presented by Eileen Handberg at ACC.25 in Chicago.
The manuscript for this trial has not been published and all assumptions are based upon the presentation.

Author

The RELIEVE-HF study: is an atrial septal shunt beneficial in HFrEF?
07 Apr 2024
Charles Fauvel provides his take on the RELIEVE-HF study outcomes presented by Gregg W. Stone at ACC.24 in Atlanta.

Author

Surgical left atrial appendage occlusion in VHD without AF: OPINION Trial
03 Sep 2025
Alex Sticchi provides his take on the results of the OPINION trial presented by Yang Wang at the ESC Congress 2025 in Madrid.

Author

Long-term beta-blocker treatment after acute myocardial infarction and preserved left ventricular ejection fraction: The REDUCE-AMI Trial
07 Apr 2024
REDUCE-AMI is a multicentre, registry-based, prospective open-label parallel-group randomised clinical trial evaluating the benefit of beta-blocker treatment in patients with acute MI and an ejection fraction >50% treated with a contemporary reperfusion strategy.
Nicola Ryan and Ali Nazmi Calik provide their take on the results which were presented...

Author

Author

Sensome announces data from two new studies showing clot-sensing guidewire successfully identifies fresh clot to support decision-making in peripheral artery disease treatment
13 Dec 2024

Early intervention in patients with asymptomatic severe aortic stenosis and left ventricular myocardial fibrosis (EVOLVED)
30 Oct 2024
Ali Nazmi Calik provides his take on the EVOLVED trial presented by Marc Dweck at TCT 2024 in Washington.

Author

Comparison of a precision care strategy with usual testing to guide management of stable patients with suspected CAD: the PRECISE randomized trial
09 Nov 2022
Alex Sticchi provides his take on PRECISE, which was presented during AHA 2022 in Chicago.

Author

Evidence base: A description of the key, so far published, studies in the space of drug coated balloons
23 Jan 2025
Authored by Hector Garcia-Garcia and Jorge Sanz-Sanchez, this article examines pivotal randomized clinical trials on drug-coated balloons in coronary artery disease. It highlights their role in managing in-stent restenosis, de novo small vessel lesions, and large vessel lesions while exploring future directions through ongoing trials.

Author

Author
